Last updated on February 2020

Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)

Brief description of study

To evaluate the efficacy of NYX-2925 versus placebo in treating the neuropathic pain associated with diabetic peripheral neuropathy.

Detailed Study Description

This is a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of NYX-2925 in subjects with neuropathic pain associated with diabetic peripheral neuropathy.

The study will be 15-18 weeks in duration, including a 1-4 week screening period (dependent upon duration of analgesic medication washout period), followed by a 14 week double-blind, randomized, placebo controlled treatment period. Subjects eligible for the study will receive either NYX-2925 or placebo during the treatment period. All subjects will receive placebo at some point during the treatment period.

Clinical Study Identifier: NCT04146896

Find a site near you

Start Over

Aptinyx Clinical Site

Murray, UT United States
  Connect »